Aurora Cannabis Projects Q2 Revenue of $50 million – $55 million

James West
|

Aurora Cannabis Inc (TSX:ACB) (NYSE:ACB) (FRA:21P) today announced projected revenue for Q2 2019 of between $50 million and $55 million – up from $11.7 million in the same quarter previous year.

The company also said in its press release that it expects to achieve positive EBIDTA, and plans to discuss its Q2 results in a conference call scheduled for February 11th.

Terry Booth, Aurora CEO said, ““Aurora continues to execute effectively across all market segments, as demonstrated by its revenue growth anticipated to exceed 68% as compared to last quarter, supported by continued strong performance in the Canadian adult consumer use market. Our consistent and high-quality
production continues to significantly ramp up as expected, fueling even further growth. Going forward, we see
sustained strong demand from the adult usage market, as evidenced by public statements from the Canadian
provinces, as well as strong patient-driven demand for medical cannabis in Canada and abroad. These factors,
together with our focus on disciplined management of operating expenses, and our growing portfolio of higher
margin products, put us in a position to rapidly achieve positive EBITDA within the next two quarters.”

Aurora Chief Corporate Officer Cam Battley will be live in Midas Letter studios today at 12 noon to discuss this press release and its contents. Midas Letter will also be publishing the latest site visit video from Aurora Sky today shortly before the interview.

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the first to hear from Midas Letter on all things Cannabis.